Merck & Co., Inc. (NYSE:MRK) CEO Kenneth C. Frazier sold 92,913 shares of the business’s stock in a transaction on Friday, February 15th. The shares were sold at an average price of $80.03, for a total transaction of $7,435,827.39. Following the sale, the chief executive officer now directly owns 784,863 shares in the company, valued at $62,812,585.89. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
NYSE:MRK traded down $0.57 during mid-day trading on Tuesday, hitting $79.24. The company’s stock had a trading volume of 9,210,257 shares, compared to its average volume of 12,753,371. Merck & Co., Inc. has a 1 year low of $52.83 and a 1 year high of $80.19. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.15 and a current ratio of 1.44. The firm has a market cap of $215.18 billion, a price-to-earnings ratio of 18.26, a PEG ratio of 2.09 and a beta of 0.62.
Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Friday, February 1st. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.03 by $0.01. Merck & Co., Inc. had a net margin of 14.71% and a return on equity of 35.10%. The company had revenue of $11 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same period in the prior year, the company earned $0.98 earnings per share. The firm’s revenue was up 5.4% on a year-over-year basis. As a group, equities research analysts predict that Merck & Co., Inc. will post 4.66 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, April 5th. Shareholders of record on Friday, March 15th will be issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 2.78%. The ex-dividend date of this dividend is Thursday, March 14th. Merck & Co., Inc.’s payout ratio is 50.69%.
A number of equities research analysts have recently weighed in on MRK shares. SunTrust Banks boosted their price objective on shares of Merck & Co., Inc. from $77.00 to $80.00 and gave the company a “buy” rating in a report on Monday, October 29th. Citigroup boosted their price objective on shares of Merck & Co., Inc. from $79.00 to $84.00 and gave the company a “buy” rating in a report on Wednesday, October 31st. Zacks Investment Research lowered shares of Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 24th. Morgan Stanley set a $81.00 price objective on shares of Merck & Co., Inc. and gave the company a “buy” rating in a report on Thursday, December 20th. Finally, BMO Capital Markets lowered shares of Merck & Co., Inc. from an “outperform” rating to a “market perform” rating and set a $80.00 price objective on the stock. in a report on Wednesday, January 23rd. Six investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $73.80.
Large investors have recently bought and sold shares of the business. PRW Wealth Management LLC acquired a new position in shares of Merck & Co., Inc. in the fourth quarter worth about $41,000. Contravisory Investment Management Inc. raised its position in shares of Merck & Co., Inc. by 186.4% in the fourth quarter. Contravisory Investment Management Inc. now owns 653 shares of the company’s stock worth $50,000 after acquiring an additional 425 shares during the period. Arlington Partners LLC raised its position in shares of Merck & Co., Inc. by 93.5% in the fourth quarter. Arlington Partners LLC now owns 828 shares of the company’s stock worth $63,000 after acquiring an additional 400 shares during the period. Advisors Preferred LLC acquired a new position in shares of Merck & Co., Inc. in the fourth quarter worth about $66,000. Finally, Financial Gravity Companies Inc. acquired a new position in shares of Merck & Co., Inc. in the fourth quarter worth about $66,000. 74.29% of the stock is currently owned by institutional investors.
Merck & Co., Inc. Company Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.
Featured Story: How is an ETF different from a mutual fund?
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.